Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

d on the mRNA that controls production of this protein.

RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks th
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Strategic Marketing ... Expertise, ... today announced that it has appointed David P.,Pauluzzi to its Board ... Partners, a Chicago-based private equity firm,specializing in the healthcare sector., ...
... DRRX ) announced today financial results for the ... were $6.6 million for the,three months ended December 31, ... 2006. Net loss for the three months ended December ... of $9.8 million for the same period in,2006., ...
... 5 Physicians Reference,Laboratory ("PRL") announced today that it ... date. Under the marketed,name COMPLeTe Care HPV, the test ... risk types of HPV which can lead to,cervical cancer., ... form of female,cancer with an incidence of over 500,000 ...
Cached Biology Technology:Transgenomic Appoints David Pauluzzi to Board of Directors 2Transgenomic Appoints David Pauluzzi to Board of Directors 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9Physicians Reference Laboratory Announces New Diagnostic for Women's Health 2
(Date:10/31/2014)... and his team have been studying the behavior ... Austrian Alps for years. They observed that ravens ... grooming and playing. However, they also observed that ... third individual. Although in about 50 % of ... up the two affiliating ravens, intervening can be ...
(Date:10/30/2014)... German . ... humans to behave socially? This is one of the ... Previous studies assumed that it is almost impossible to ... Max Planck Institute for Evolutionary Biology have now demonstrated ... the cooperative behaviour of others. However, the possibilities available ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus ... criminal justice technology solutions for public safety, ... it has deployed exciting enhancements to its ... analytics to provide actionable intelligence and focused ... continues to drive technological innovation through identifying ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2
... Could our mother,s diet at the time we are conceived ... is at the heart of a new study based on ... We inherit our DNA the genetic blueprint that ... DNA from our mothers and 50% from our fathers. Apart ...
... responsible for some of the worst air quality conditions worldwide ... changes in land use and population density, according to a ... Field of the University of Toronto. "During the late ... fire-prone during drought years, marking the period when one of ...
... BEVERLY, Mass., Feb. 17 LocatePLUS Holdings ... business-to-government provider of investigative, identity validation, and ... 26, 2009 election of an entirely independent ... independent Board through the consent of a ...
Cached Biology News:'Experiment of nature' examines how mother's diet may impact on child's health 2'Experiment of nature' examines how mother's diet may impact on child's health 3Atmospheric scientists trace the human role in Indonesian forest fires 2LocatePLUS Announces Election of Independent Board 2LocatePLUS Announces Election of Independent Board 3LocatePLUS Announces Election of Independent Board 4
... Application: Pyronin Y is most ... green to selectively and differentially stain ... In a dichromatic dye solution, Pyronin ... green stains DNA green. ...
... cassette is designed to allow ... The prokaryotic promoter gb2 driving the ... slightly modified version of the Em7 ... than the generally used Tn5 promoter. ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: